Literature DB >> 27595362

Sarcomas of Soft Tissue and Bone.

Andrea Ferrari, Uta Dirksen, Stefan Bielack.   

Abstract

The definition of soft tissue and bone sarcomas include a large group of several heterogeneous subtypes of mesenchymal origin that may occur at any age. Among the different sarcomas, rhabdomyosarcoma, synovial sarcoma, Ewing sarcoma and osteosarcoma are aggressive high-grade malignancies that often arise in adolescents and young adults. Managing these malignancies in patients in this age bracket poses various clinical problems, also because different therapeutic approaches are sometimes adopted by pediatric and adult oncologists, even though they are dealing with the same condition. Cooperation between pediatric oncologists and adult medical oncologists is a key step in order to assure the best treatment to these patients, preferably through their inclusion into international clinical trials.
© 2016 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2016        PMID: 27595362     DOI: 10.1159/000447083

Source DB:  PubMed          Journal:  Prog Tumor Res        ISSN: 2296-1887


  22 in total

1.  Pan-sarcoma characterization of lncRNAs in the crosstalk of EMT and tumour immunity identifies distinct clinical outcomes and potential implications for immunotherapy.

Authors:  Deyao Shi; Shidai Mu; Feifei Pu; Binlong Zhong; Binwu Hu; Muradil Muhtar; Wei Tong; Zengwu Shao; Zhicai Zhang; Jianxiang Liu
Journal:  Cell Mol Life Sci       Date:  2022-07-16       Impact factor: 9.207

2.  The mevalonate pathway promotes the metastasis of osteosarcoma by regulating YAP1 activity via RhoA.

Authors:  Xing Du; Yunsheng Ou; Muzi Zhang; Kai Li; Wei Huang; Dianming Jiang
Journal:  Genes Dis       Date:  2020-11-21

3.  Long-Term Efficacy and Safety of Anlotinib as a Monotherapy and Combined Therapy for Advanced Sarcoma.

Authors:  Weitao Yao; Xinhui Du; Jiaqiang Wang; Xin Wang; Peng Zhang; Xiaohui Niu
Journal:  Onco Targets Ther       Date:  2022-06-14       Impact factor: 4.345

4.  The neutrophil-to-lymphocyte ratio as a novel independent prognostic factor for multiple metastatic lung tumors from various sarcomas.

Authors:  Hiromasa Yamamoto; Kei Namba; Haruchika Yamamoto; Tomohiro Toji; Junichi Soh; Kazuhiko Shien; Ken Suzawa; Takeshi Kurosaki; Shinji Otani; Mikio Okazaki; Seiichiro Sugimoto; Masaomi Yamane; Katsuhito Takahashi; Toshiyuki Kunisada; Takahiro Oto; Shinichi Toyooka
Journal:  Surg Today       Date:  2020-08-03       Impact factor: 2.549

5.  Inhibition of P53-mediated cell cycle control as the determinant in dedifferentiated liposarcomas development.

Authors:  Mossane Stocker; Louis-Romée Le Nail; Hubert De Belenet; Jay S Wunder; Irene L Andrulis; Nalan Gokgoz; Nicolas Levy; Jean-Camille Mattei; Sylviane Olschwang
Journal:  Am J Cancer Res       Date:  2021-06-15       Impact factor: 6.166

Review 6.  Sarcomas of the sellar region: a systematic review.

Authors:  Fernando Guerrero-Pérez; Noemi Vidal; Macarena López-Vázquez; Reinaldo Sánchez-Barrera; Juan José Sánchez-Fernández; Alberto Torres-Díaz; Nuria Vilarrasa; Carles Villabona
Journal:  Pituitary       Date:  2021-02       Impact factor: 4.107

7.  Gene expression profiles for an immunoscore model in bone and soft tissue sarcoma.

Authors:  Jingyuan Fan; Xinyi Qin; Rongquan He; Jie Ma; Qingjun Wei
Journal:  Aging (Albany NY)       Date:  2021-05-04       Impact factor: 5.682

8.  Persistent Shoulder Pain in Young Male: Osteosarcoma.

Authors:  Punitha Arinima; Azlina Ishak
Journal:  Korean J Fam Med       Date:  2018-07-04

9.  Feasibility of Targeting Traf2-and-Nck-Interacting Kinase in Synovial Sarcoma.

Authors:  Tetsuya Sekita; Tesshi Yamada; Eisuke Kobayashi; Akihiko Yoshida; Toru Hirozane; Akira Kawai; Yuko Uno; Hideki Moriyama; Masaaki Sawa; Yuichi Nagakawa; Akihiko Tsuchida; Morio Matsumoto; Masaya Nakamura; Robert Nakayama; Mari Masuda
Journal:  Cancers (Basel)       Date:  2020-05-16       Impact factor: 6.639

10.  GAPLINC is a predictor of poor prognosis and regulates cell migration and invasion in osteosarcoma.

Authors:  Shian Liao; Sijia Zhou; Chao Wang
Journal:  Biosci Rep       Date:  2018-10-09       Impact factor: 3.840

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.